Table 1. Baseline demographic data and patient characteristics when starting sorafenib.
| Demographics/characteristics | |
|---|---|
| Gender [n (%)] | |
| Male | 146 (77) |
| Female | 44 (23) |
| Age, years [n (%)] | |
| ≤72 | 103 (54) |
| >72 | 87 (46) |
| Median (range) | 72 (35–83) |
| HBV [n (%)] | |
| Absent | 162 (85) |
| Present | 28 (15) |
| HCV [n (%)] | |
| Absent | 95 (50) |
| Present | 95 (50) |
| Alcohol abuse [n (%)] | |
| Absent | 173 (91) |
| Present | 17 (9) |
| ECOG-PS [n (%)] | |
| 0 | 96 (51) |
| ≥1 | 94 (49) |
| Child–Pugh score [n (%)] | |
| A | 138 (73) |
| B | 52 (27) |
| Intrahepatic lesions [n (%)] | |
| Absent | 13 (7) |
| Present | 177 (93) |
| Maximum size of the intrahepatic lesion, >50 mm [n (%)] | |
| Absent | 124 (65) |
| Present | 66 (35) |
| Number of intrahepatic lesions, >7 [n (%)] | |
| Absent | 77 (41) |
| Present | 113 (59) |
| MVI [n (%)] | |
| Absent | 123 (65) |
| Present | 67 (35) |
| EHM [n (%)] | |
| Absent | 105 (55) |
| Present | 85 (45) |
| MVI or/and EHM [n (%)] | |
| Absent | 67 (35) |
| Present | 123 (65) |
| BCLC stage [n (%)] | |
| B | 41 (22) |
| C | 149 (78) |
| AFP, ng/mL [n (%)] | |
| ≤400 | 106 (56) |
| >400 | 84 (44) |
| Pre-treatment [n (%)] | |
| Absent | 21 (11) |
| Present | 169 (89) |
| Initial dose of sorafenib, 800 mg/day | |
| Absent | 13 (7) |
| Present | 177 (93) |
| Average daily dose [n (%)] | |
| >400 mg | 98 (52) |
| ≤400 mg | 92 (48) |
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; ECOG-PS, Eastern Cooperative Oncology Group performance status; MVI, macrovascular invasion; EHM, extrahepatic metastasis; BCLC, Barcelona clinic liver cancer; AFP, alpha-fetoprotein